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Abstract
Vascular endothelial growth factor (VEGF) plays a central role in angiogenesis. A number of studies
have focused on its role in health and disease and discussed the possibility of VEGF as both a
therapeutic tool and target based on its specific actions on vascular proliferation and cell survival. On
one side, anti-VEGF therapies are at the fore-front of treatment of many solid tumors, but blockade
of VEGF carries collateral effects such as hypertension and renal damage largely due to abnormalities
in the microvasculature. On the other hand, recent clinical and experimental evidence has shown
the feasibility of using VEGF administration to protect ischemic tissues such as the myocardium or the
kidney via stimulation of microvascular proliferation and repair. In this commentary, we discuss the
possibility and potential mechanisms of using intra-renal administration of VEGF to preserve the renal
microcirculation and, consequently, decrease progressive renal injury in chronic renovascular
disease. Targeted administration of VEGF may constitute a novel stand-alone or co-adjuvant
intervention with the potential to become a part of a comprehensive plan to protect renal function.
Introduction
Chronic kidney disease affects over 15% of the US adult
population [1]. Chronic kidney disease patients have a
five fold increase in co-morbid conditions and 50% higher
rate of hospitalization compared to the general popula-
tion [1]. Chronic renovascular disease is a progressive
disease that currently accounts for up to 16% of all cases
of chronic kidney disease and end-stage renal disease
[2,3], with an incidence which increases with age and
makes it a major health problem and economic burden
worldwide. The main etiology of chronic renovascular
disease is renal artery narrowing/stenosis (usually due to
atherosclerosis), which currently affects 18-40% of
patients older than 65 [2]. The most frequent therapeutic
approach to treat renal artery stenosis is by catheter-
based interventions via renal angioplasty. However,
despite its increasing use and technical success in
resolving a renal vascular obstruction, recovery of renal
function and/or the resolution of hypertension are still
observed in about one third of the patients.
Despite major advances in imaging and interventional
techniques, little progress has been made in improving
the relatively poor outcomes of catheter-based interven-
tions in patients with chronic renovascular disease. Thus,
identification of potential therapies targets to slow, stop
or even reverse the progressive renal injury seen in
chronic renovascular disease would provide a huge
benefit. New experimental models are giving us hope
that we may find new approaches to stop the continuous
increase in end stage renal disease observed for the past 2
decades [4]. Some of these approaches are targeted
therapeutic interventions. For example, cell-based ther-
apy for the kidney has gained momentum in the past
5 years. The use of pluripotent progenitor cells looks like
a promising and relatively safe renoprotective therapy
[5-7], although the mechanism of action is still under
debate. By incorporation into the tissue and inducing
powerful autocrine and paracrine stimulation of sur-
rounding cells around the damaged renal tissue [8],
progenitor cells trigger a prolonged cascade of events
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One prominent cytokine stimulated in the kidney by
these cell-based interventions is vascular endothelial
growth factor (VEGF) [7]. VEGF is a pivotal angiogenic
and pro-survival factor, which operates in concert with
other factors to promote cell division, migration,
endothelial cell survival, and vascular sprouting. The
net effect is to dynamically generate, repair, and
maintain microvascular networks, which extend from
major vessels to play crucial roles in diffusion exchange
of nutrients and metabolites in virtually all tissues in the
body. VEGF also promotes migration of endothelial
cell progenitors [9,10], and these include vascular
proliferation not only during developmental phases
but also in tissues subjected to an ischemic insult. The
angiogenic effects of VEGF and its potential application
as a renal therapeutic tool are the main focus of this
commentary. For a comprehensive review of the biology
of VEGF, which is beyond the scope of this commentary,
please refer to [11,12].
Anti-VEGF therapies underline its importance
The clear-cut actions of VEGF in angiogenesis have been
the engine for copious research on targeting VEGF in
cancer, where it plays a central role in generating blood
vessels that promote the growth of the tumor. Anti-
VEGF therapies are already part of the first line of
treatment in colon cancer [13] and their use in other
types of solid tumors is under extensive investigation
[14,15]. However, this intervention is not free of
collateral damage: adverse effects include hypertension
and renal damage, which are possibly due, in part, to
significant microvascular damage in the renal parench-
yma [16]. Furthermore, it has been reported that down-
regulation of the VEGF pathway in normal organs can
lead to microvascular disturbances and even regression
of blood vessels, which could be compounded by
concurrent pathological conditions [17]. Beyond raising
the need for caution in the use of these agents, these
findings emphasize the importance of this key angio-
genic cytokine in health and disease.
How can VEGF induce renoprotection?
Structural damage, dysfunction, and/or loss of the
microvessels, known as microvascular disease, is a key
contributor to the progression of organ damage [18-22].
Extending from major vessels to ensure diffusion
exchange of nutrients and metabolites in the tissues,
microvessels are vital for the normal function of any
organ. Previous experimental and clinical evidence has
shown that VEGF administration protects the micro-
circulation in different pathological milieus, such as in
the ischemic myocardium [23,24] and hind-limb ische-
mia [25]. Furthermore, seminal work by Kang et al. [26]
and David Basile’s group [27,28] in rodents has shown
the importance of renal VEGF for slowing the progres-
sion of renal injury as well as the feasibility of using
VEGF therapy as a renoprotective tool.
These findings suggest that VEGF has a central role in the
kidney and give us the rationale to use an intra-renal
administration of exogenous VEGF as a potential therapy
to protect the kidney. Using a model of chronic renal
artery stenosis as a surrogate of chronic renovascular
disease, our studies have demonstrated that a progressive
microvascular loss in the stenotic kidney correlates with
progressive renal damage, that renal VEGF progressively
decreases in the kidney, and that the decrease in VEGF in
turn correlates with the progressive deterioration of renal
function and microvascular rarefaction in the stenotic
kidney[29-32]. Administration of VEGF was shown tobe
beneficial. Intra-renal VEGF improved renal function and
restored microvascular density by stimulating microvas-
cular proliferation in the stenotic kidney, underscoring
the importance of renal microvascular integrity for renal
function. A single intra-renal administration of VEGF in
the stenotic kidney augmented the glomerular and
tubular expression of this cytokine, and also increased
the expression of its key mediators. For example, intra-
renal administration of VEGF may promote an increase
in Akt, a key pro-survival factor, and Ang-1/Tie-2 [30],
which together with VEGF [33] play important roles
in promoting vascular proliferation and accelerating
the maturation of the newly generated vessels [34,35]
as well as in the mobilization and homing of cell pro-
genitors into ischemic tissues to promote neovascular-
ization [36]. Another pivotal mediator of VEGF that we
observed to be increased by this intervention is endothe-
lial nitric oxide synthase, which may augment nitric
oxide bio-availability [30]. Endothelial nitric oxide
synthase-derived nitric oxide plays an important role
in the initial microvascular sprouting induced by VEGF
[37] and the nitric oxide-VEGF axis protects tubular
and glomerular cells from injury [38]. Overall, our work
indicates that intra-renal administration of VEGF is a
feasible therapeutic approach for the ischemic kidney. It
largely restored the VEGF-angiogenic cascade, stimulat-
ing microvascular proliferation and probably the repair
that preserved the renal microcirculation [30]. Function-
ally, this resulted in preservation of the microcirculation
and renal function, decreased renal fibrosis, and
improved responses to renal angioplasty [29,30].
The road ahead
Although others [26,28] and we [29,30] have shown that
intra-renal administration of VEGF improved the
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exercised in translating this into clinical practice
[29,30]. First, VEGF is also a potent vasodilator that
may decrease blood pressure and this could reduce its
tolerance should it be used in clinical practice. However,
we used the maximally tolerated dose in our studies that
was shown  to be effective in inducing vascular proliferation
and increasing perfusion of the ischemic myocardium in
humans without causing adverse collateral effects [24].
Other than a minimal and transient decrease in blood
pressure in the animals, the intra-renal administration of
VEGF was free of adverse effects in our studies, offering
the possibility of increasing the frequency of adminis-
tration if needed. Second, VEGF may increase the
permeability of newly generated vessels. High perme-
ability may decrease the functionality of these neovessels
and may in turn facilitate renal injury in chronic
renovascular disease by allowing the leakage of injurious
cytokines to the extra-vascular space. Finally, since VEGF
has been shown to promote tumor growth and it has
been suggested to play a role in promoting athero-
sclerosis, refinement of the technical side of its admin-
istration (dose, route, frequency) and careful selection
and follow-up of the patients is crucial to avoid
undesired effects of this intervention should it progress
into clinical trials. Although I am aware that the swine
model used in our studies may represent the very early
stage of chronic renovascular disease, it did show that
VEGF administration reduced renal damage in the
stenotic kidney. This intervention promoted microvas-
cular proliferation, maturation, and cell survival. Likely,
not only by improving its renal bioavailability but also
by stimulating key players in the VEGF-induced angio-
genic cascade (e.g. endothelial nitric oxide synthase, Akt,
angiopoietins). These results suggest that the multi-step
process of angiogenesis was stimulated in the kidney
(Figure 1), and they also indicate that preserving the renal
microvascular architecture was renoprotective [29,30].
Conclusion
It is possible that severity of renal microvascular disease is
underestimated at the moment in treatment of chronic
renovascular disease. The process of microvascular
damage may define the “window of opportunity” to
successfully intervene in patients with chronic renovascu-
lar disease and could be a major player behind the
relatively poor outcomes of renal angioplasty and the
progressive nature of chronic renovascular disease. Accu-
rate assessment of the renal microvascular density and
function in humans is indeed challenging. However,
clinically available high-resolution imaging techniques to
quantify microvascular distribution and evaluation of
microvascular function (e.g. ultrasound, CT imaging)
could serve as tools to better determine the severity of
microvascular and renal damage and thereby help to
predict the outcomes of renal angioplasty. Targeted use of
VEGF has shown promising renoprotective effects in
clinically relevant experimental settings [26,29,30].
Those results may inform the carefully designed prospec-
tive experimental and clinicalstudiesthat are needed to
determine the feasibility and optimal therapeutic use of
VEGF,bothasastand-alonetreatmentor,possibly,asaco-
adjuvant intervention for the treatment of patients with
chronic renovascular disease.
Abbreviation
VEGF, Vascular endothelial growth factor.
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Figure 1: Schematic illustration summarizing the effects of an
intra-renal administration of VEGF in the stenotic kidney,
in a model of chronic RVD
Exogenous VEGF stimulated angiogenic and pro-survival mediators that
promote cell survival and MV proliferation and repair, consequently
decreasing renal injury and improving renal function. Abbreviations:
RVD: renovascular disease; MV: microvascular; eNOS: endothelial nitric
oxide synthase; Ang-1: angiopoietin-1.
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